The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 SpikeGlycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated andNon-SARS-CoV-2 Infected, COVID-19 Convalescents, Persons Vaccinated With Pfizer-BioNTechBNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1 nCov-19 AZD1222 Vaccines, andConvalescent COVID-19 Patients That Have Subsequently Been Vaccinated. A PotentialDifference in the Immunoglobulin Concentrations of the Pfizer-BioNTech BNT162b2 Vaccine,Moderna mRNA-1273 vaccine and the AstraZeneca ChAdOx1-S Vaccine Will be Uncovered. ThisKnowledge About the Mucosal Immunity Will be Important for Further Designing of VaccineStrategies.
Not Provided
Diagnostic Test: Blood- and saliva tests
Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
Inclusion Criteria:
- Written informed consent
- Both Hospital staff as well as non-health care workers will be invited to
participate
Exclusion Criteria:
- Individuals not fulfilling the inclusion criteria or declining blood or saliva
collection.
- Exclusion criteria are neck breathers (tracheostomy/laryngectomy patients) or other
nasopharyngeal or oropharyngeal anomalies that do not allow for sampling using
Salivette.
Not Provided
Lennart Friis-Hansen, Dr.med.
61145916
lennart.jan.friis-hansen@regionh.dk
Not Provided